bioRxiv Science⌕ Search

Biology subjects

Gold, S. M.

Publications and source records attributed to Gold, S. M..

3 recordsLinked to original sources

Comparable neural pathways link psychological stress and brain health in health and multiple sclerosis

Clinical and neuroscientific studies suggest a link between psychological stress and reduced brain health - in healthy humans and patients with neurological disorders. However, it is unclear which neural pathways mediate between stress and brain health and whether these pathways are similar in health and disease. Here, we applied an Arterial-Spin-Labeling MRI stress task in 42 healthy persons and 56 with multiple sclerosis. We tested whether brain-predicted age differences ("brain-PAD"), a highly sensitive structural brain health biomarker derived from machine learning, mirror functional connectivity between stress-responsive regions. We found that regional neural stress responsivity did not differ between groups. Although elevated brain-PAD indicated worse brain health in patients, anterior insula-occipital functional connectivity correlated with brain-PAD in both groups. Grey matter variations contributed similarly to brain-PAD in both groups. These findings suggest a generic connection between stress and brain health whose impact is amplified in multiple sclerosis by disease-specific vulnerability factors.

neuroscience↗

Complement-associated loss of CA2 inhibitory synapses in the demyelinated hippocampus impairs memory

The complement system is implicated in synapse loss in the MS hippocampus, but the functional consequences of synapse loss remain poorly understood. Here, in post-mortem MS hippocampi with demyelination we find that deposits of the complement component C1q are enriched in the CA2 subfield, are linked to loss of inhibitory synapses and are significantly higher in MS patients with cognitive impairments compared to those with preserved cognitive functions. Using the cuprizone mouse model of demyelination, we corroborated that C1q deposits are highest within the demyelinated dorsal hippocampal CA2 pyramidal layer, and co-localized with inhibitory synapses engulfed by microglia/macrophages. In agreement with the loss of inhibitory perisomatic synapses, we further found that Schaffer collateral feedforward inhibition but not excitation was impaired in CA2 pyramidal neurons and accompanied by a reduced spike output. Ultimately, we show that these electrophysiological changes were associated with an impaired encoding of social memories. Together, our findings identify CA2 as a critical circuit in demyelinated intrahippocampal lesions and memory dysfunctions in MS.

neuroscience↗

Short-term aerobic training does not improve memory functioning in relapsing remitting multiple sclerosis - a randomized controlled trial

BackgroundOnly few aerobic exercise intervention trials specifically targeting cognitive functioning have been performed in MS.\n\nObjective and methodsThis randomized controlled trial aimed to determine the effects of aerobic exercise on cognition in relapsing-remitting MS. The primary outcome was verbal memory (Verbal learning and memory test, VLMT). Patients were randomized to an intervention group (IG) program or a waitlist control group (CG). Patients in the IG exercised according to an individually tailored training schedule (with 2-3 sessions per week for 12 weeks). The primary analysis was carried out using the intention-to-treat (ITT) sample with ANCOVA adjusting for baseline scores.\n\nResults77 RRMS patients were screened and 68 participants randomized (CG n=34; IG n=34). The sample comprised 68% females, had a mean age of 39 years, a mean disease duration of 6.3 years, and a mean EDSS of 1.8. No significant effects were detected in the ITT analysis for the primary endpoint VLMT or any other cognitive measures. Moreover, no significant treatment effects were observed for quality of life, fatigue, or depressive symptoms.\n\nConclusionThis study failed to demonstrate beneficial effects of aerobic exercise on cognition in RRMS.\n\nThe trial was prospectively registered at clinicaltrials.gov (NCT02005237).

clinical trials↗